Jack Schuler Purchases 13,900 Shares of Biodesix (NASDAQ:BDSX) Stock

Biodesix, Inc. (NASDAQ:BDSX) Director Jack Schuler bought 13,900 shares of the business’s stock in a transaction on Monday, August 10th. The shares were acquired at an average price of $24.25 per share, with a total value of $337,075.00. Following the completion of the purchase, the director directly owned 527,110 shares of the company’s stock, valued at approximately $12,782,417.50. The trade was a 2.71% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink.

Biodesix Price Performance

Shares of BDSX traded down $0.09 during midday trading on Wednesday, hitting $24.22. The company’s stock had a trading volume of 90,916 shares, compared to its average volume of 630,207. Biodesix, Inc. has a one year low of $5.26 and a one year high of $25.52. The company’s fifty day simple moving average is $20.02 and its two-hundred day simple moving average is $15.96. The company has a quick ratio of 2.85, a current ratio of 2.85 and a debt-to-equity ratio of 5.12. The stock has a market capitalization of $255.55 million, a price-to-earnings ratio of -7.64 and a beta of 0.56.

Biodesix (NASDAQ:BDSX) last posted its earnings results on Wednesday, August 5th. The company reported ($0.71) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.90) by $0.19. The firm had revenue of $26.86 million for the quarter, compared to analysts’ expectations of $26.03 million. Biodesix had a negative net margin of 26.97% and a negative return on equity of 788.19%. As a group, equities analysts expect that Biodesix, Inc. will post -2.68 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. XTX Topco Ltd grew its stake in Biodesix by 99.4% in the 2nd quarter. XTX Topco Ltd now owns 205,647 shares of the company’s stock valued at $58,000 after purchasing an additional 102,494 shares during the period. Cetera Investment Advisers purchased a new position in shares of Biodesix in the 4th quarter worth about $68,000. DRW Securities LLC bought a new position in Biodesix during the fourth quarter valued at about $105,000. Allworth Financial LP bought a new position in Biodesix during the second quarter valued at about $112,000. Finally, Millennium Management LLC purchased a new stake in Biodesix during the third quarter worth about $113,000. Hedge funds and other institutional investors own 20.96% of the company’s stock.

Analyst Upgrades and Downgrades

BDSX has been the topic of a number of analyst reports. Canaccord Genuity Group upped their price target on Biodesix from $27.00 to $35.00 and gave the company a “buy” rating in a research report on Monday. HC Wainwright reiterated a “buy” rating and issued a $27.00 price target (up from $26.00) on shares of Biodesix in a report on Thursday, August 6th. Roth Capital initiated coverage on Biodesix in a research report on Wednesday, June 24th. They set a “buy” rating and a $32.00 target price on the stock. Finally, Weiss Ratings upgraded shares of Biodesix from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, June 12th. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, Biodesix has a consensus rating of “Moderate Buy” and a consensus target price of $31.33.

Biodesix Company Profile

Biodesix, Inc is a commercial-stage molecular diagnostics company headquartered in Boulder, Colorado, that develops and delivers blood-based tests to improve the diagnosis and management of lung diseases, including lung cancer. The company integrates advanced proteomic and, more recently, genomic technologies to offer noninvasive testing solutions designed to guide clinical decision-making. Biodesix operates a CLIA-certified and CAP-accredited laboratory, allowing it to process patient samples at scale and maintain rigorous quality standards.

The company’s flagship product, VeriStrat®, is a proteomic test that stratifies patients with non-small cell lung cancer into groups more likely to benefit from specific therapies.